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List of Abbreviations 
 
2-NBDG    2-N-7-nitrobenz-2-oxa-1,3-diazol-4-yl amino-2-
deoxyglucose  
3PGA  glycerophosphate, 3-phosphoglycerate 
4-OHT  4-hydroxytamoxifen  
4E-BP  4E-binding protein  
6PGL 6-phosphogluconolactone  
7AAD  7-Aminoactinomycin D 
Abs  Antibodies 
AKT  Protein kinase B (PKB) 
AMPK  5' AMP-activated protein kinase 
ATCC  American Type Culture Collection 
BrdU  5-bromo-2'-deoxyuridine 
BSA  Bovine serum albumin 
CBP80  cap-binding protein 80 




CE-TOFMS  Capillary electrophoresis time-of-flight mass 
spectrometry  
DAB  3,3′-Diaminobenzidine 
DMSO  Dimethyl sulfoxide 
eEF2K  Eukaryotic translation elongation factor 2 kinase  
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
eIF Eukaryotic Initiation Factor  
eIF4B  Eukaryotic translation initiation factor 4B  
EMT  Epithelial- mesenchymal transition  
EtOH Ethanol 
F1,6BP  Fructose 1,6-bisphosphate  
FBS Fetal bovine serum 
FCCP  Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone 
FDA  US Food and Drug Administration 




G6P  Glucose-6-phosphate  
GAP GTPase-Activating Protein 
GBM  Glioblastoma 
GFAP  Glial fibrillary acidic protein 
GICs Glioma initiating cells 
Glut1  Glucose transporter 1  
Grb10 Growth factor receptor-bound protein 10  
Hk2  hexokinase2  
huKO  humanized Kusabira-Orange  
MDM2  Mouse double minute 2 homolog 
mTORC1 Mammalian target of rapamycin complex 1 
Nf1  Neurofibromin 1 
NSPCs  Primary neural stem/progenitor cells  
OCR  Oxygen consumption rate 
p53  Tumor protein p53 




PBS  Phosphate-buffered saline 
PDGFR  Platelet-derived growth factor receptor 
PEP  Phosphoenol pyruvate  
PGC1α PPAR-γ coactivator 1α 
PI3K Phosphoinositide-3-kinase  
PKM2  Pyruvate kinase isoenzyme type M2  
PTEN  Phosphatase and tensin homolog 
PVDF  Polyvinylidene difluoride  
RB1 Retinoblastoma 1 
ROS Reactive oxygen species 
RTK  Receptor tyrosine kinases  
Ru5P  Ribulose-5-phosphate  
S6  Ribosomal protein S6 
S7P Sedoheptulose 7-phosphate  
SVZ  Subventricular zone  




Tsc1  Tuberous Sclerosis 1 
TuJ1  Neuron-specific class III beta-tubulin 
Ulk1  Unc-51 Like Autophagy Activating Kinase 1 









Although abnormal metabolic regulation is a critical determinant of cancer 
cell behavior, it is still unclear how an altered balance between ATP 
production and consumption contributes to malignancy. Here the results 
show that disruption of this energy balance efficiently suppresses aggressive 
malignant gliomas driven by mTOR complex 1 (mTORC1) hyperactivation. 
In a mouse glioma model, mTORC1 hyperactivation induced by conditional 
Tsc1 deletion increased numbers of glioma-initiating cells (GICs) in vitro 
and in vivo. Metabolic analysis revealed that mTORC1 hyperactivation 
enhanced mitochondrial biogenesis, as evidenced by elevations in oxygen 
consumption rate (OCR) and ATP production. Inhibition of mitochondrial 
ATP synthetase was more effective in repressing sphere formation by Tsc1-
deficient glioma cells than that by Tsc1-competent glioma cells, indicating a 
crucial function for mitochondrial bioenergetic capacity in GIC expansion. 
To translate this observation into the development of novel therapeutics 
targeting malignant gliomas, I screened drug libraries for small molecule 




of Tsc1-deficient cells compared to controls. Several compounds able to 
preferentially inhibit mitochondrial activity, dramatically reducing ATP 
levels and blocking glioma sphere formation were identified. In human 
patient-derived glioma cells, nigericin, which reportedly suppresses cancer 
stem cell properties, induced AMPK phosphorylation that was associated 
with mTORC1 inactivation and induction of autophagy, and led to a marked 
decrease in sphere formation with loss of GIC marker expression. 
Furthermore, malignant characteristics of human glioma cells were markedly 
suppressed by nigericin treatment in vivo. Thus, targeting mTORC1-driven 
processes, particularly those involved in maintaining a cancer cell’s energy 














Abnormal metabolic regulation is critical for malignant transformation 
leading to cancer(1,2). In particular, a tumor cell must maintain a proper 
energy balance between ATP production and its consumption to support the 
cell’s heightened proliferation, survival and undifferentiated status. 
Historically, it has been believed that, even in the presence of oxygen, cancer 
cells generate energy mainly by glycolysis rather than through mitochondrial 
oxidative phosphorylation (OXYPHOS), a concept known as the Warburg 
effect(3). However, several previous studies using tumor cells lacking 
mitochondrial DNA challenged the Warburg hypothesis, because these data 
showed that tumors depend on mitochondrial respiration for the maintenance 
of fully transformed malignant phenotypes(4-7).  
 
Metabolic regulation and Mitochondrial Activity 
Recent studies demonstrated that mitochondrial activity is essential for 




Accordingly, several small molecule compounds targeting mitochondrial 
function have been investigated for their anti-cancer effects(11). For example, 
numerous clinical studies of metformin, which inhibits mitochondrial 
complex I, have established the efficacy of this agent for cancer treatment. 
Other compounds that decrease mitochondrial bioenergetic capacity also 
have anti-tumor effects, therefore, targeting mitochondrial energetics is 
deemed to be a promising basis for new cancer therapies. 
 
Mammalian target of rapamycin (mTOR)  
The mammalian target of rapamycin (mTOR) is a serine/threonine protein 
kinase that belongs to the phosphoinositide-3-kinase (PI3K)-related protein 
kinase family. mTOR participates in two complexes, designated mTOR 
complex 1 (mTORC1) and 2 (mTORC2), both of which phosphorylate 
multiple substrates(12-14).  
Both mTOR complexes are large; mTORC1 having six regulatory proteins, 
mammalian lethal with sec-13 protein 8 (mLST8, also known as GbL) with 
unknown role and even their loss doesn’t affect mTORC1 activity to known 




which is mTORC1 inhibitor, and the Tti1/Tel2 complex regulating the 
assembly and stability of mTORC1. Unlike mTORC2, mTORC1 have two 
specific regulatory proteins, regulatory-associated protein of mammalian 
target of rapamycin (raptor) which has an important role in the regulation of 
mTORC1 stability, localization and binding to substrates. Finally, proline-
rich Akt substrate 40 kDa (PRAS40) a mTORC1 inhibitor (12). 
However, mTORC2 have seven known regulatory protein components, three 
of them are unique to mTORC2, rapamycin-insensitive companion of mTOR 
(rictor) which is very important in regulation of the assembly and substrate 
binding to mTORC2, mammalian stress-activated map kinase-interacting 
protein 1 (mSin1) regulating the assembly and interaction of mTORC2 to 
SGK1 protein, and protein observed with rictor 1 and 2 (protor1/2) increases 
mTORC2 mediated activation of SGK1. The remaining regulatory 
components of mTORC2, like mTORC1 are mLST8, DEPTOR, Tti1 and 
Tel2 complex (12). 
 
mTORC1 signaling 




of AKT. AKT phosphorylates tuberous sclerosis complex (TSC) 2 and 
blocks the GAP activity of the TSC complex. The TSC complex exhibits 
GAP activity towards the small G protein Rheb and inhibits its ability, 
therefore, TSC complex is a negative regulator of mTORC1. Among 
mTORC1’s substrates are the p70 ribosomal protein S6 kinases (p70S6Ks), 
eukaryotic Initiation Factor (eIF), 4E-binding proteins (4E-BPs), Ulk1, 
Lipin1, and Growth factor receptor-bound protein 10 (Grb10). 
Phosphorylation of 4E-BP1 by mTORC1 leads to its dissociation from eIF4E, 
allowing recruitment of eIF4G to the 5′cap and translation initiation. 
p70S6Ks phosphorylate ribosomal protein S6, eukaryotic translation 
elongation factor 2 kinase (eEF2K), cap-binding protein 80 (CBP80), and 
eukaryotic translation initiation factor 4B (eIF4B), all of which stimulate 
protein synthesis (15,16).  
 
mTOR signaling and Mitochondrial activity 
On one hand, mTORC1 activation induces aerobic glycolysis by up-
regulating pyruvate kinase isoenzyme type M2 (PKM2). On the other hand, 




mitochondrial activation and OXYPHOS. For example, mTORC1 is crucial 
for the mitochondrial activation mediated by PPAR-g coactivator 1a 
(PGC1a) and the transcription factor Ying-Yang 1 (YY1)(15,16). Another 
study has demonstrated that mTORC1 stimulates the synthesis of nucleus-
encoded mitochondrial proteins via 4E-BPs, resulting in increased 
mitochondrial ATP production(17). Since mRNA translation is the most 
energy-consuming process in the cell, mTORC1 coordinates both energy 
consumption and production, contributing to malignant progression. 
 
Glioblastoma  
Glioblastoma (GBM) is the most common high-grade malignant glioma in 
humans. GBM is categorized as a WHO grade IV astrocytoma, a very 
aggressive, invasive and destructive brain tumor (18). The major problem in 
glioma therapy is due to the infiltrative behavior of glioma cells and its 
ability to transfer into normal brain regions. Although the recent advances in 
the treatment of glioma, the number of patients diagnosed with glioma 
increase with a maximum survival of one year to one and half year. These 




or identification of signaling and molecular pathways involved in the 
development of glioma continues to have several challenges (19).  
 
Glioma stem cells 
Stem cells can be defined as the cells have the ability to self- renewal and 
differentiation into mature cells of a particular tissue. Stem cells are rare in 
most tissues. As a result, isolation of stem cells is very  difficult and to study 
the biology and characteristics of stem cells, they must be isolated, purified 
and identified very carefully (20).  
It is clear that normal stem cells and cancer sharing the self-renewal ability. 
There are many evidences show that cancer and normal stem cells sharing a 
lot of signaling pathways which is involved in regulation and development. 
From these pathways, the Notch signaling pathway, Sonic hedgehog 
pathway and Wnt signaling which are involved in oncogenesis in cancer 
tissues, these pathways may be involved also in the regulation of self-
renewal of normal tissue stem cells (21). 
The presence of cancer stem cells was first identified in the acute myeloid 




identify AML stem cells from the rest AML cells, which had a less 
proliferative capacity. More recent, the principle of cancer stem cells has 
been extended to different types of cancers such as, breast cancer and 
glioblastoma. The advances in research indicate that many types of tumor 
cells can be organized into hierarchies, containing malignant cancer stem 
cells, which have a high proliferative capacity, to more differentiated tumor 
cells, with a lower proliferative ability (22). 
 Numerous studies have identified a tumor cell population that can initiate 
glioma development. These cells are called glioma-initiating cells (GICs) 
and are conceptually recognized as “glioma stem cells”(23). It is the behavior 
of these GICs that determines the malignant phenotypes of GBM.  
 
Genetic mutations in GBM 
Alterations in several signaling cascades are known to affect gliomagenesis, 
including the RTK/RAS/PI3K pathway (EGFR, PDGFR, Nf1 and PTEN), 
the p53 pathway (TP53, CDKN2A/ARF and MDM2), and the RB pathway 
(RB1, CDKN2A/p16INK4A, CDKN2B and CDKN2C)(24). Consistent with 




activation, the phosphorylation status of substrates of mTORC1 is a 
prognostic indicator for glioma patients(25-27).  
 
mTORC1 signaling in GBM 
Although the mTORC1 pathway is clearly a major player in gliomagenesis 
and malignant progression, mTORC1 inhibitors such as rapamycin and its 
analogs have failed to successfully treat GBM patients in the clinic. It is 
speculated that a feedback loop may exist in which mTOR inhibition by the 
allosteric inhibitors stimulates PI3K activation, supporting survival of tumor 
cells. Moreover, although mTOR ATP-competitive inhibitors and 
PI3K/mTOR inhibitors that fully inhibit substrate phosphorylation have been 
developed(28), these compounds are likely to have unwanted side-effects 
and may cause serious damage to normal tissues. Therefore, there is a 








Aim of the present study 
 
Previously, It has been reported that hyperactivation of mTORC1 in a murine 
inducible Tsc1 gene deletion resulted in early tumor onset in an EGFRvIII-
driven mouse glioma model (p16Ink4ap19Arf deficient background)(29). In 
that glioma model, Tsc1 deletion increased tumor mass and enhanced 
microvascular formation leading to intracranial hemorrhage, indicating that 
mTORC1 hyperactivation promotes malignant phenotypes of glioma in vivo. 
In the present study, first aim is to investigate the molecular mechanism by 
which mTORC1 hyperactivation causes the malignant phenotypes of glioma 
cells. Second aim is to identify small molecule compounds that may be 










Rosa26-CreERT2 mice were the kind gift of Dr. Tyler Jacks (Massachusetts 
Institute of Technology). p16Ink4a+/- p19Arf+/- mice were obtained from the 
Mouse Models of Human Cancers Consortium of NCI-Frederick (30,31). 
Tsc1f/f mice were purchased from the Jackson Laboratory. For 
transplantation experiments using mouse and human glioma cells, BALB/c 
nu/nu mice (4-week-old females) were purchased from Sankyo Laboratory 
Service. All animal experiments were approved by the Committee on Animal 
Experimentation of Kanazawa University and performed following the 
University’s Guidelines for the Care and Use of Laboratory Animals.  
 
Mouse glioma model  
Glioma-bearing mice were established as previously described(29). Briefly, 
primary neural stem/progenitor cells (NSPCs) were isolated from 
subventricular zone (SVZ) regions of Tsc1f/f; Rosa26-CreERT2 mice 




plates (Corning) in serum-free NSPC medium, which contained DMEM/F12, 
B27 and 50 U/ml penicillin/ 0.5% streptomycin (all from Life Technologies), 
plus 20 ng/ml human FGF2 (Wako) and 20 ng/ml human EGF (Sigma). For 
preparation of retrovirus carrying EGFRvIII, Plat-E cells, provided by Dr. 
Toshio Kitamura (Institute of Medical Science, University of Tokyo), were 
transfected with pGCDN-EGFRvIII-IRES- humanized Kusabira-Orange 
(huKO), provided by Dr. Masafumi Onodera, National Research Institute for 
Child Health and Development (32). Retrovirus-containing supernatants 
were concentrated by centrifugation at 6,000xg for 16 hr. Cultured primary 
NSPCs were infected with pGCDN-EGFRvIII-IRES-huKO-expressing 
retroviruses for 24 hr and maintained in culture until transplantation. 
EGFRvIII-transduced NSPCs were dissociated into single cells, resuspended 
in 5% FBS/PBS, and 1x104 cells were inoculated into the brains of 
anesthetized Balb/c nu/nu mice. For nigericin treatment in vivo, 1x106 
huKO+ cells (Tsc1f/f; Rosa-CreERT2) were subcutaneously transplanted into 
female Balb/c nu/nu mice. To delete the Tsc1 gene in tumor cells in vivo, 
recipient mice were injected intraperitoneally (ip) with 1 mg/day tamoxifen 




glioma cells, tumor tissues were dissociated with the Brain Tumor 
Dissociation Kit (Miltenyi Biotec) and huKO+ cells were sorted using a BD 
FACSAria III instrument (BD). For transplantation of glioma cells, 100, 
1,000 or 10,000 huKO+ cells were inoculated into the brains of recipient mice.  
 
Cell culture 
To delete the Tsc1 gene in mouse glioma cells in vitro, huKO+ cells (Tsc1f/f; 
Rosa-CreERT2) were cultured for 3 days in complete NSPC medium 
(containing EGF+FGF2) plus 0.1 µM 4-hydroxytamoxifen (4-OHT, Sigma). 
Cultures were washed clean of 4-OHT and cultured for another 2 days in 
complete NSPC medium. For sphere formation assays, single-cell 
suspensions were prepared using Accutase (Innovative Cell Technologies, 
Inc.) and filtered through a 40-µm cell strainer (BD), followed by culture for 
7 days in NSPC medium with or without EGF+FGF2 and containing 1% 
methylcellulose (Wako). Human patient-derived GBM cells, termed TGS-
01 and TGS-04, were established as described previously(33). Use of these 
human materials and protocols were approved by the Ethics Committees of 




level in glioma cells, sodium pyruvate stock solution (100 mM, Thermo 
Fisher Scientific) was added to normal NSPC medium (final concentration 
was increased from 0.5 to 1.5 mM).  
 
CD133 Expression 
To determine CD133 expression in the human glioma TGS-01 human 
patient-derived cells, TGS-01 cells treated with 0.5µM nigericin in adherent 
cell culture condition for 4 days. Next, cells were collected, centrifuged and 
filtered.  Filtered cells were stained with anti-CD133 antibody (Ab) 
(Miltenyi Biotec #130-098-129), incubated on ice for 30 min, and analyzed 
by flow cytometry. 
 
Drug screening 
Libraries used for drug screening were: FDA-approved drug library (ENZO; 
CB-BML-2841J0100), ICCB known bioactives library (ENZO; CB-BML-
2840J0100), kinase inhibitor library (ENZO; CB-BML-2832J0100), fatty 
acid library (ENZO; CB-BML-2803J0100) and phosphatase inhibitor library 




compounds, we assayed nigericin (Sigma Aldrich), amoxapine (Wako), 
A23187 (Sigma Aldrich), valinomycin (Sigma Alderich), rottlerin (Abcam), 
auranofin (Abcam), clodronic acid (Cayman), moxifloxacin (Sigma Aldrich), 
nifidipine (Sigma Aldrich), minocycline (Santa Cruz Biotechnology), 
clindamycin (Sigma Aldrich) and pentamidine (Sigma Aldrich). Briefly, 
control and Tsc1-deficient glioma cells were treated with a compound at 
three doses (1/500, 1/2,000, and 1/10,000 dilution of provided compounds in 
the library) in 384-well plates (Corning) for 48 hr, followed by analysis of 
cell viability as mentioned below. The "Index for drug sensitivity of Tsc1-
deficient glioma cells" was calculated as the ratio of value2/value1 at a 
specific dose of a compound, where value1 was for the drug efficacy in Tsc1-
deficient glioma cells (e.g., 0.2 means 80% reduction), and value2 was for 
the drug efficacy in control cells (e.g., 0.8 means 20% reduction). An Index 
>1.0 means that Tsc1-deficient glioma cells were more sensitive than control 







Western blotting  
Proteins were extracted with lysis buffer [0.1 M Tris (pH 6.7), 4% SDS, 
phosphatase inhibitor (Thermo Fisher Scientific), complete mini (Roche)] 
and quantified using a bicinchoninic acid (BCA) protein assay kit (Thermo 
Fisher Scientific). Proteins (5 µg) were fractionated by SDS-PAGE and 
transferred onto 0.45 mm polyvinylidene difluoride (PVDF) membranes 
(Millipore). Membranes were blocked in 5% (w/v) BSA/0.02% (v/v) Tween 
20/PBS and incubated with primary antibodies (Abs) overnight at 4°C, 
followed by incubation with HRP-conjugated secondary Abs (GE 
Healthcare) and detection with ECL Prime (GE Healthcare). Primary Abs 
recognizing the following proteins were used: Tsc1 (#4906), pp70S6K 
(T389) (#9234), p70S6K (#2708), pS6(S235/236) (#4858), S6 (#2217), p4E-
BP1 (T37/46) (#2855), 4E-BP1 (#9644), pAMPK alpha (T172) (#2535), 
AMPK alpha (#2532) (all from Cell Signaling Technologies, 1:1000), actin 
(Sigma-Aldrich #A5441, 1:2000), Nestin (Millipore #AB5922, 1:500), 
Olig2 (IBL #18953, 1:500), GFAP (BD #556328, 1:1000) , TuJ1 (Covance 






Total RNA was extracted using the RNeasy Mini Kit (Qiagen). Total RNA 
was reverse-transcribed to cDNA using Super Script Reverse Transcriptase 
(Life technologies). Genomic and mitochondrial DNAs were extracted with 
50 mM NaOH followed by neutralization with 1 M Tris-HCl.  Real-time 
quantitative PCR was performed with Mx3000P (Stratagene). The following 
cycle parameters were used: denaturation at 95˚C for 30 sec, annealing for 
30 sec at 58˚C, and elongation for 30 sec at 72˚C. Sequences of sense and 
antisense primers used were as follows:  
 
Slc2a1 sense; 5`CAGTTCGGCTATAACACTGGTG3`, Slc2a1 antisense; 
5`GCCCCCGACAGAGAAGATG3`, Hk2 sense; 
5`TGATCGCCTGCTTATTCACGG3`, Hk2 antisense; 
5`AACCGCCTAGAAATCTCCAGA3`, Pkm2 sense; 
5`GCCGCCTGGACATTGACTC3` , Pkm2 antisense; 
5`CCATGAGAGAAATTCAGCCGAG3`, Atp5g1 sense; 
5`CCAGAGGCCCCATCTAAGC3`, Atp5g1 antisense; 




5`GCCGCTGTCTGTTCCATTC3`, Cox5a1 antisense; 
5`GCATCAATGTCTGGCTTGTTGAA3`, Cycs sense; 
5`CCAAATCTCCACGGTCTGTTC3`, Cycs antisense; 
5`ATCAGGGTATCCTCTCCCCAG3`, Actb sense; 
5`GGCTGTATTCCCCTCCATCG3`, Actb antisense;  
 
Intracellular ATP quantification 
Intracellular ATP levels were quantified using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) following the manufacturer’s 
instructions. Briefly, cells were cultured in 96- or 384-well Ultra low 
attachment plates (Corning), and the luminescence representing the ATP 
level was measured by Infinite Pro 200 (Tecan). 
 
Cell viability assay 
Cell viability was assessed using the Cell Counting Kit-8 (Dojindo) 
following the manufacturer’s instructions. Briefly, cells were incubated with 
WST-8 reagent for 3 hrs and absorbance at 450 nm was compared using 




Quantification of metabolites 
For capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) 
analysis, three independent samples of control or Tsc1-deficient mouse 
glioma cells (3×106) that had been cultured in NSPC medium without 
EGF+FGF2 were lysed with methanol (1 ml) containing 25 µM internal 
standards (L- methionine sulfone, MES and CSA)(Wako), and homogenized 
to inactivate enzymes. The sample (400 µl) was transferred to a fresh tube, 
and 200 µl of chloroform was added. The mixture was centrifuged at 10,000 
× g for 3 min at 4°C, and 400 µl of the upper aqueous layer was centrifugally 
filtered through a Millipore 5-kDa cutoff filter to remove proteins. The 
filtrate samples (320µl) were lyophilized and dissolved in 25 µl Milli-Q 
water containing 200 µM reference compounds (3-aminopyrrolidine, 
Adlrich, and trimesate, Wako) prior to CE-TOFMS analysis (34,35). 
 
Mitochondrial membrane potential   
To determine mitochondrial membrane potential, cells were treated for 30 
min with small molecule compounds at the concentrations indicated in the 




30 min at 37°C in 5% CO2. Measurements of membrane potential were 
performed by flow cytometry. 
 
Apoptosis 
For Annexin V staining, TGS-01 human patient-derived glioma cells were 
treated with 1 µM nigericin for 6 hr, Then, cells incubated with PE-
conjugated Annexin- V and 7AAD in Annexin V binding buffer (BD 
Biosciences) in accordance with the manufacturer’s protocol. Measurements 
of Apoptosis were performed by flow cytometry. 
 
Reactive oxygen species (ROS) generation   
For analysis of mitochondria-derived ROS, cells were treated with 1 µM 
nigericin for 6 hr, incubated with 5 µM Mitosox Red (Life Technologies) for 
30 min, washed twice with 5% FBS/PBS, and stained with 7AAD (BD 
Biosciences) to exclude dead cells. Measurements of ROS were performed 






Oxygen consumption assay 
The OCR was measured using an XF24 Extracellular Flux Analyzer 
(Seahorse Bioscience) according to manufacturer's protocol. For analysis of 
the effects of small molecule compounds on OCR, AGS cells (a human 
gastric cancer cell line， from ATCC) were seeded at 4x104 cells/well in 
500 µl supplemented culture medium (DMEM, Seahorse Bioscience 
#102365). OCR was measured at preset time intervals while the instrument 
automatically carried out preprogrammed additions of oligomycin (1 µM, 
Cell Signaling Technology #9996), FCCP (400 nM, Sigma #C2920) and 
antimycin A (1 µM, Sigma #A8674).  
 
Cell cycle analysis  
Cell cycle analysis was performed as previously described(36). Briefly, 
BrdU (10 µM) was added to the cultures and incubation continued at 37ºC 
for 30 min. Cells were collected and washed with PBS, followed by the 
addition of 70% EtOH (-30ºC) for 16 hr. Cells were then incubated with 2N 
HCl/0.5% Triton X-100 for 30 min at room temperature (RT), followed by 




min at RT. Cells were stained with anti-BrdU-FITC Ab (BD Biosciences) 
for 1 hr at RT while avoiding light. Labeled cells were resuspended in PBS 
containing 1% bovine serum albumin and 7AAD (BD Biosciences), 
followed by cell cycle analysis by flow cytometry.  
 
Tumor xenografts  
Cells (1x106/100µl/inoculation site) were mixed with Matrigel Matrix 
(Fisher Scientific, Corning, NY, USA, no. 356234) (1:1.4 ratio) and 
subcutaneously transplanted into each of the two flanks of anesthetized 
female Balb/c nu/nu mice. Nigericin (4 mg/ml) or auranofin (12 mg/ml) 
dissolved in DMSO was mixed with corn oil (1:4 ratio). Nigericin (4 
mg/kg/day, ip injection, every 2 days) or auranofin (12 mg/kg/day for 2 days, 
ip injection) was administered on day 1 after inoculation of TGS-01 cells. 
Tumor volume was measured using a conventional formula: volume (V) = 
(W2 × L)/2 where W=width and L=Length.  
Immunohistochemistry 
Tumors derived from xenografted patient-derived GBM cells were fixed 




Sections were stained with hematoxylin and eosin (HE). For immunostaining, 
sections were treated with Target Retrieval Solution (Dako), and stained with 
anti-Ki67 (BD#550609, 1:100), followed by visualization with a HRP-
conjugated secondary Ab (GE Healthcare) and the DAB Peroxidase 
Substrate Kit (VECTOR). Stained sections were counterstained with 
hematoxylin and viewed using a microscope (Axio ImagerA1, Carl Zeiss).  
 
Statistical analyses 
Student’s t test was used when comparing two groups, one-way (ANOVA) 
followed by Bonferroni’s post hoc test when comparing more than two 
groups. For survival analysis in Fig.1C, differences in survival rate were 
analyzed by log-rank test. Calculations of significance were performed using 














mTORC1 hyperactivation expands mouse GICs in vitro and in vivo  
To investigate the role of mTORC1 in GIC expansion, the previously 
described mouse glioma model in which mTORC1 is activated by a TAM-
inducible system(29) was used. Briefly, NSPCs of Tsc1f/f; Rosa26-CreERT2 
mice (p16Ink4a-/-;p19Arf-/- background) were infected with retrovirus carrying 
EGFRvIII gene plus the huKO gene as a marker and injected these infected 
cells into the basal ganglia of immunocompromised mice. To activate 
mTORC1 in glioma tissue in vivo, TAM was administrated to NSPC-bearing 
recipient mice on day 5 post-transplantation. After gliomas had developed 
(at about 3 weeks post-transplantation), huKO+ cells were collected from 
digested brain tissues of recipient mice and isolated glioma cells by flow 
cytometry. Efficient deletion of the Tsc1 gene in this system has been 
previously confirmed by genomic DNA analysis(29).  
To determine whether Tsc1 deficiency affected sphere formation, 
huKO+ cells were cultured in ultra-low attachment dishes under standard 




growth factors, EGF and FGF2. Tsc1 deficiency significantly increased the 
number of spheres formed (Fig.1), indicating that the sphere-forming cells 
had expanded upon mTORC1 activation.  
To evaluate the tumor-initiating capacity of glioma cells in vivo, 
recipient mice were inoculated with 100, 1,000 or 10,000 freshly isolated 
huKO+ glioma cells. It has been found that Tsc1 deficiency promoted tumor 
development and accelerated the death of recipients compared to Tsc1-
competent glioma cells (Fig.2). When as few as 10 huKO+ cells were 
transplanted, only Tsc1-deficient glioma cells were capable of producing 
gliomas, but not control cells. Thus, GIC frequency is increased in vivo by 
mTORC1 activation. 	
 
mTORC1 activation causes growth factor-independent proliferation of 
mouse GICs  
To investigate how mTORC1 activation affects the proliferation and survival 
of murine GICs, the effect of Tsc1 deletion on sphere formation in vitro was 
analyzed. Tsc1f/f; Rosa26-CreERT2 glioma cells were allowed to form 




4-OHT efficiently induced Tsc1 deletion in these sphere cells was confirmed, 
as evidenced by the disappearance of Tsc1 protein from lysates of sphere 
cells that had been cultured with 4-OHT (Fig.3). However, unexpectedly, 
there was no difference in the number of spheres formed by control and Tsc1-
deficient cells cultured in the presence of EGF+FGF2 (Fig.4). This 
discrepancy may be due to differences between culture conditions in vitro 
and microenvironmental conditions in vivo. Although level of 
phosphorylation in 4E-BP1 was slightly up-regulated, those of S6 and 
p70S6K were almost normal in Tsc1-deficient glioma cells cultured under 
these conditions (Fig.3). It is speculated that, mTORC1 is fully activated 
when cytokines are abundant, and that levels of these factors are much higher 
in vitro than in vivo, therefore, Tsc1 deletion might not be able to further 
enhance such signaling in this culture condition. When control and Tsc1-
deficient glioma cells were cultured in the absence of EGF+FGF2, the size 
and number of spheres formed in these control glioma cell cultures was 
decreased compared to those in control cultures containing growth factors, 
however, Tsc1-deficient glioma cells showed comparable sphere forming 




mTORC1 hyperactivation maintains sphere-forming capacity even when 
growth factors are withdrawn. Consistent with this observation, although 
levels of S6 and 4E-BP phosphorylation in control glioma cells cultured 
without growth factors were lower than those with growth factors, such 
down-regulation of phosphorylation due to growth factor depletion was not 
observed in Tsc1-deficient cells (Fig.3). Since the results did not show a 
remarkable change in the expression of Olig2, a glioma stem cell marker, in 
Tsc1-deficient glioma cells (Fig.5), which assume that Tsc1 deficiency 
promotes the proliferation and/or survival of GICs. Thus, mTORC1 
hyperactivation induces GIC expansion that is independent of growth factors.  
 
Increased sensitivity of Tsc1-deficient glioma cells to glucose depletion  
Next the mechanism by which mTORC1 activation affects GIC growth in 
mouse glioma model was dissected. Although the metabolic status of whole 
glioma cells might not necessarily be identical to that of GICs due to tumor 
heterogeneity, metabolite levels were assessed in control and Tsc1-deficient 
glioma cells in culture in vitro using CE-TOFMS (34,35). Several 




fructose 1,6-bisphosphate (F1,6BP), glycerophosphate, 3-phosphoglycerate 
(3PGA), and phosphoenol pyruvate (PEP), were significantly up-regulated 
(Fig.6). The same was true for components of the pentose phosphate pathway, 
including 6-phosphogluconolactone (6PGL), ribulose-5-phosphate (Ru5P), 
and sedoheptulose 7-phosphate (S7P) (Fig.6). These findings suggested that 
glucose metabolism might be stimulated in Tsc1-deficient cells.  
When gene expression levels were analyzed, Results showed that 
mRNAs encoding glycolytic enzymes such as glucose transporter 1 (Glut1), 
hexokinase2 (Hk2), and pyruvate kinase M2 (PKM2) were all elevated by 
mTORC1 activation (Fig.7). These data indicate that mouse glioma cells 
experiencing mTORC1 hyperactivation show increased dependence on 
glucose. 
 
Enhanced mitochondrial ATP production supports mTORC1-driven 
GIC expansion 
Metabolomics analysis showed that lactate levels in glioma cells were not 
significantly affected by Tsc1 deletion (Fig.6). These data suggested that the 




to enhanced mitochondrial OXPHOS rather than to the production of lactate 
via typical glycolysis. To determine OXPHOS in these cells, OCR was 
evaluated and found that it was significantly increased in Tsc1-deficient 
glioma cells (Fig.8). In addition, the expression levels of mitochondria-
associated genes were up-regulated by Tsc1 deletion (Fig.9). Consistent with 
this enhanced mitochondrial activity, ATP levels were increased in Tsc1-
deficient cells compared to controls (Fig.10, left). To assess whether this 
increase in ATP in Tsc1-deficient cells was in fact due to enhanced OXPHOS, 
the cells were treated with oligomycin, an ATP synthetase inhibitor. 
Interestingly, while oligomycin had only a modest effect on ATP levels in 
control cells, it dramatically reduced ATP levels in Tsc1-deficient cells 
(Fig.10, right).  
Consistent with the marked ATP reduction in oligomycin-treated 
Tsc1-deficient glioma cells, oligomycin also profoundly suppressed sphere 
formation by Tsc1-deficient cells compared to controls (Fig.11). These 
results indicate that mTORC1 hyperactivation stimulates mitochondrial ATP 





Drug screening to identify small molecule compounds that can suppress 
sphere formation by Tsc1-deficient mouse glioma cells 
The new application of a known drug, called drug repositioning or drug 
repurposing, has been a beneficial approach for developing novel therapies 
for human diseases. With this in mind, I assessed whether this mouse glioma 
model would be useful for drug screening to identify known compounds able 
to specifically inhibit the aggressive phenotypes of glioma cells. To this end, 
I evaluated the effects of numerous small molecule compounds from 
commercially available existing drug libraries (a total of 1,301 compounds) 
on the proliferation/survival of control and Tsc1-deficient mouse glioma 
cells. To compare the efficacy of an individual compound on control vs. 
Tsc1-deficient cells, First the inhibitory effect was estimated for each 
compound on both types of cells, and then the ratio of the inhibitory effect 
on Tsc1-deficient cells compared to its effect on control cells was calculated; 
this ratio was termed the "Index for drug sensitivity of Tsc1-deficient cells" 
(see Experimental Procedures).  
Most compounds screened exhibited an Index of about 1.0 ± 0.5 




cells. Several compounds showed low Index values, suggesting that these 
drugs were less effective in inhibiting the growth of Tsc1-deficient cells than 
that of control cells. For example, I found that the EGFR inhibitors gefitinib 
and erlotinib showed less efficacy in Tsc1-deficient cells than in control cells 
(Fig.13). Several genotoxic reagents, including mitoxantrone and topotecan, 
were also less efficacious in Tsc1-deficient cells (Fig.14), suggesting that 
mTORC1 hyperactivation allows glioma cells to resist conventional 
chemotherapy. In contrast to the above, several compounds were identified 
that were highly effective in inhibiting the growth of Tsc1-deficient glioma 
cells compared to that of control cells (Fig.15).  
From the first screening, 13 drugs were selected (nigericin, 
amoxapine, A23187, auranofin, rottlerin, valinomycin, minocycline, 
nifedipine, pentamidine, cyclosporine, clodronic acid, clindamycin and 
moxifloxacin) that showed reproducible increased efficacy in Tsc1-deficient 
cells compared to controls. The concentrations of these compounds used in 
this screening was approximately 0.5-30 µM.  
Next, I screened the selected compounds for those that caused a 




the previous observation that oligomycin treatment triggered a significant 
reduction in ATP in the former. I found that 5 drugs (nigericin, A23187, 
auranofin, rottlerin and valinomycin) clearly reduced intracellular ATP levels 
when used at less than 20 µM (Fig.16). Most of these drugs showed greater 
inhibitory effects on Tsc1-deficient cells than on control cells, although there 
were differences in efficacy among these compounds. I confirmed that these 
5 compounds also had a greater suppressive effect on sphere formation by 
Tsc1-dificent glioma cells than on that by control cells (Fig.17), suggesting 
that the screening system could efficiently identify drug candidates in 
therapeutic approach for mTORC1-driven glioma.  
 To investigate whether the selected compounds could affect the 
behavior of human GBM cells as well as mouse Tsc1-deficient glioma cells, 
I applied each agent to human patient-derived GBM cell lines (TGS-01 and 
TSG-04 cells). Although it is unclear exactly which GBM sub-type these 
cells represent, they appear to have characteristics similar to the proneural 
type (rather than to the mesenchymal type) because they express relatively 
high levels of CD133, which is a proneural sub-type marker(37). A recent 




GBMs, proneural GBMs show elevated expression and activation of 
elements of the PI3K-AKT-mTORC1 pathway(24). Therefore, like the Tsc1-
deficient mouse glioma cells used in this study, human TGS-01 and TSG-04 
GBM cells may exhibit relatively high levels of mTORC1. I found that all 
the 5 drug compounds reduced ATP in TGS-01 cells compared to untreated 
GBM cells (Fig.18).  
All compounds also induced abnormality in mitochondrial 
membrane potential (Fig.19). Nigericin (a K+/H+ ion exchanger) induced 
mitochondrial membrane hyperpolarization, as previously reported(38), 
whereas A23187 (Ca2+ ionophore), rottlerin (K+ ionophore) and valinomycin 
(K+ ionophore) triggered depolarization (Fig.19), indicating that an 
abnormality of ion channels causes mitochondrial dysfunction. Cells 
exposed to auranofin, a gold (I)-phosphine derivative used to treat 
rheumatoid arthritis, also showed depolarization, because this agent 
reportedly induces the mitochondrial membrane permeability transition, 
which is manifested as mitochondrial swelling and loss of membrane 
potential(39). This means that treatment with most of these selected 




mitochondrial ATP production.  
Since it was previously reported that nigericin and valinomycin affect 
mitochondrial respiratory chain (40), Conferment of their effects was 
performed. After downregulation of OCR by ATP synthase inhibition 
(oligomycin treatment), it was recovered by valinomycin (as expected), 
because valinomycin is an uncoupler (Fig.20). In contrast, nigericin 
treatment blocked the respiratory chain and maintained its suppression even 
after addition of FCCP (an uncoupler), indicating that nigericin is an efficient 
inhibitor of mitochondrial bioenergetics. Thus, compounds selected by a 
combination of the “Index for drug sensitivity in Tsc1-deficient mouse 
glioma cells” and their effects on ATP levels induce mitochondrial 
dysfunction. These data demonstrate that the drug screening system used in 
this study can efficiently select small molecule compounds capable of 
disrupting a glioma cell’s energy balance.  
 
Nigericin suppresses malignant phenotypes of human patient-derived 
GBM cells  




potential for human GBM. Among the candidates, nigericin has previously 
been selected by a drug screening program as being capable of targeting 
cancer stem cell properties, which are induced by the epithelial-
mesenchymal transition (EMT). Therefore, I focused on nigericin to 
determine if this compound could have advantage in suppression of 
malignant phenotypes of human GBM cells in vitro and in vivo. I found that 
nigericin could indeed effectively reduce sphere formation by human GBM 
cells in culture (Fig.21). While nigericin treatment blocked the cell cycle, 
specifically S-phase entry as determined by BrdU incorporation (Fig.22), it 
did not induce significant apoptosis (Fig.23). Mitochondrial ROS were up-
regulated in glioma cells as detected by MitoSOX (Fig.24), indicating that 
nigericin induces mitochondrial dysfunction. Moreover, expression levels of 
the glioma stem cell markers, Olig2 and CD133, were dramatically 
downregulated during culture with nigericin (Fig.25, 26). These data 
indicate that nigericin suppresses proliferation of GBM cells, associated with 
the loss of stem cell properties. Interestingly, nigericin clearly triggered 
AMPK phosphorylation that was associated with marked inhibition of 




ATP levels stimulates an anti-tumor signaling cascade that includes AMPK 
activation and mTORC1 inactivation. mTOR inhibition and AMPK 
activation are both known to induce autophagy(12), and, as expected, 
nigericin dramatically induced autophagy in glioma cells as determined by 
an observed increase in the LC3-II/LC3-I ratio (Fig.27).  
To investigate whether nigericin inhibits sphere formation due to 
abnormality in energy control, concentration of sodium pyruvate was 
increased in culture media, because pyruvic acid supplies energy to cells 
through the OXYPHOS in the presence of oxygen. As a result, addition of 
sodium pyruvate mitigated the inhibitory effect of low concentration, but not 
higher concentration (>0.1 µM), of nigericin on sphere formation (Fig.28). 
These data suggest that low dose of nigericin inhibits sphere formation due 
to partial, but not complete, impairment of mitochondrial energy production. 
Although remarkable changes of energy signals were not observed with such 
low dose of nigericin, presumably due to subtle changes below detectable 
limits, these data support an idea that energy imbalance causes dysfunction 
of GICs.  




glioma growth in vivo. Immunocompromised mice were injected with 
human GBM cells and tumor development was monitored. Indeed, tumor 
volume (Fig.29) was greatly reduced in nigericin-treated recipient mice. 
Histological analyses showed that important histological hallmarks for GBM 
malignancy, such as remarkable vasculature formation and pseudopalisading 
necrosis, were observed in control tumor tissues. In contrast, these malignant 
characteristics dramatically disappeared by nigericin treatment in vivo 
(Fig.30). Also, results showed down-regulation of Ki67 staining, by 
nigericin treatment in vivo (Fig.31). When the effect of nigericin on tumor 
cell growth in recipient mice bearing Tsc1Δ/Δ or control mouse glioma cells 
were evaluated, I found that nigericin profoundly suppressed the growth of 
Tsc1-deficient tumors in vivo, consistent with in vitro results (Fig.32).  
In addition, when I evaluated the effects of other candidate agents 
auranofin, A23187, Rottlerin and valinomycin on human GBM cells, I found 
that all of these compounds suppressed sphere formation on both human 
patient derived glioma cell lines TGS-01 and TGS-04 (Fig.33,34). Then, 
auranofin was selected to perform an in vivo experiment because this agent 




mentioned above. auranofin treatment of glioma-bearing mice resulted in a 
significant reduction in GBM growth in vivo (Fig.35). Like nigericin, 
Histological analyses after auranofin treatment showed a remarkable 
reduction in vasculature formation and pseudopalisading necrosis which 
observed in control tumor tissues, but not in auranofin treated tissues (Fig. 
36). Immunohistochemical analysis showed a clear reduction in the 
proliferation as evidenced by the proliferation marker ki67 after auranofin 
treatment in vivo (Fig.37).  
These data clearly indicate that this screening system based on an 
mTORC1-driven glioma model is useful for selecting compounds able to 








































Figure 1. Sphere formation assay in control and Tsc1 deficient cells. 
Quantitation of sphere formation by huKO+ cells isolated from recipient 
mice that had been treated with (Tsc1Δ/Δ) or without (control) TAM to delete 
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Figure 2. Tsc1 deletion leads to GIC expansion in vivo. Kaplan-Meier 
analysis of survival of recipient mice inoculated with 100, 1,000 or 10,000 




















Figure 3. Tsc1 deletion and mTORC1 pathway. Western blot to detect the 
indicated proteins in control and Tsc1Δ/Δ cells. Deletion of Tsc1 gene in vitro 
was induced with 4-OHT treatment to prepare Tsc1Δ/Δ cells (see 
Experimental Procedures). Lysates were prepared from control and Tsc1Δ/Δ 



















































































Figure 4. Expansion of GICs induced by Tsc1 deletion is independent of 
growth factors. Quantitation of sphere formation of control and Tsc1Δ/Δ cells 
cultured with/without EGF+FGF2. Data are the mean sphere number (left 

















Figure 5. Olig2 expression in control and Tsc1 deleted mouse glioma cells. 
Western blot to detect Olig2 in control and Tsc1Δ/Δ cells cultured without 
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Figure 6. Metabolomics Analysis. Scheme showing quantitation of changes 
to metabolites in the pentose phosphate and glycolysis pathways that were 
associated with Tsc1 deletion in huKO+ cells. Control and Tsc1-deficient 
cells were cultured without EGF+FGF2 and subjected to quantification of 
metabolites. Data for each metabolite are the mean ratio ± SD relative to the 























































































Figure 7. Gene expression analysis of Glycolysis associated genes.  qRT-
PCR analysis of Glut1, Hk2, and Pkm2 mRNA levels in the control and Tsc1-
deficient cells. Data were normalized to b-actin and are presented as the 















































Figure 8. Effects of Tsc1 deficiency on oxygen consumption in mouse 
glioma cells. Quantitation of OCR by control and Tsc1-deficient cells 














Figure 9. Mitochondrial associated genes levels in control and Tsc1 
deficient mouse glioma cells. qRT-PCR analysis of Atp5g1, Cox5a1, and 
cytochrome c mRNA levels. Data are the mean fold change ± SD relative to 


























































































Figure 10. Effects of Oligomycin treatment ATP levels in control and 
Tsc1 deficient mouse glioma cells. Quantitation of intracellular ATP levels 
in control and Tsc1-deficient cells that were cultured without EGF+FGF2 
and treated with the ATP synthetase inhibitor oligomycin for 12 hr. Data are 






















































































Figure 11. Effects of Tsc1 deficiency and Oligomycin treatment on 
sphere formation in mouse glioma cells. Quantitation of sphere formation 
by control and Tsc1-deficient cells that were cultured without EGF+FGF2 
and treated with the indicated concentrations of oligomycin. Data are the 














Figure 12. Drug screening for small molecule compounds that have a 
greater growth inhibitory effect on Tsc1-deficient glioma cells than on 
control cells. The "Index for drug sensitivity of Tsc1-deficient glioma cells" 
(see Experimental Procedures) for 1,301 compounds is shown. Control and 
Tsc1-deficient cells were treated with the indicated small molecule 
compounds, followed by analysis of cell viability 48 hr later 






























































Figure 13. Examples of EGFR "drug-resistant" profiles. Quantitation of 
relative viability of control or Tsc1-deficient cells that were cultured without 
EGF+FGF2 and treated with the indicated concentrations of the indicated 


























Figure 14. Examples of Genotoxic agents "drug-resistant" profiles. 
Quantitation of relative viability of control or Tsc1-deficient cells that were 
cultured without EGF+FGF2 and treated with the indicated concentrations 
of the indicated drugs. Data are expressed as the mean % cell viability 





































































































































































































































































































Figure 15. Examples of "drug-sensitive" profiles. Quantitation of relative 
viability of control or Tsc1-deficient cells that were cultured without 
EGF+FGF2 and treated with the indicated concentrations of the indicated 








Figure 16. Effect of selected small molecule compounds on ATP levels of 
mouse glioma cells. Quantitation of the effects of the indicated small 
molecule compounds on ATP levels in control and Tsc1-deficient cells that 
were treated with the indicated compounds at the indicated concentrations. 
Cells were treated for (6 hr) was followed by analysis of intracellular ATP 
levels. Data are the mean ratios ± SD relative to untreated control cells. 
Statistical analyses were performed to detect differences between control and 
Tsc1-deficient cells at each drug concentration.   
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Figure 17. Effect of selected small molecule compounds on sphere-
forming ability of control and Tsc1-deficient glioma cells. Quantitation of 
the effects of the indicated small molecule compounds on sphere formation 
in control and Tsc1-deficient cells that were treated with the indicated 
compounds at the indicated concentrations. cells were cultured to allow 
sphere formation. Data are the mean sphere number ± SD. Statistical 
analyses were performed to detect differences between treated and untreated 
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Figure 18. Effects of selected small molecule compounds on ATP levels 
on human patient-derived TGS-01 glioma cells. Quantitation of 
intracellular ATP levels in human GBM patient-derived TGS-01 cells that 
were treated with the indicated concentrations of the indicated compounds 
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Figure 19. Effects of selected small molecule compounds on 
mitochondrial membrane potential on TGS-01 human patient derived 
glioma cells.  Analysis of mitochondrial membrane potential in TGS-01 
cells that were treated for 30 min with the indicated concentrations of the 
indicated compounds, followed by determination of mitochondrial 
membrane potential using JC-10. Representative flow cytometric data for 










Figure 20. Effects of selected small molecule compounds on oxygen 
consumption rate.  Quantitation of changes in OCR in AGS cells that were 
treated first with oligomycin to inhibit ATP synthetase activity and then with 
DMSO (vehicle control), nigericin (1 µM) or valinomycin (1 µM) (n=3). 




























Figure 21. Therapeutic potential of nigericin for treatment of human 
GBM in vitro. Quantitation of sphere formation by (left) TGS-01 and (right) 
TGS-04 human patient-derived GBM cells that were treated with the 
























































































Figure 22. Cell cycle analysis after Nigericin treatment in TGS-01 
human glioma cells.  Cell cycle analysis of TGS-01 cells that were treated 
with 5 µM nigericin for 3 hrs. Data are the mean percentage of cells ± SD in 
























Figure 23. Effect of Nigericin treatment on Apoptosis on TGS-01.  
Representative Annexin V flow cytometric analysis in TGS-01 cells that 
were treated with 1 µM nigericin for 6 hr. Black, no staining; blue, DMSO 
















Figure 24. Effect of Nigericin treatment on Mitochondrial ROS 
generation on TGS-01.  Representative MitoSOX flow cytometric 
analysis of mitochondrial ROS in TGS-01 cells that were treated with 1 µM 
nigericin for 6 hr. Gray line, no staining; black dashed, DMSO control; black 










































Figure 25. Glioma stem cells markers expression. Expression of GIC 
markers of TGS-01 cells that treated with 0.1 or 0.5µM nigericin in adherent 



























Figure 26. Expression of CD133 in TGS-01 cells that treated with 0.5µM 
nigericin in adherent cell culture condition for 4 days. Representative 
flow cytometric analysis of CD133 expression. Gray line, no staining; black 

















Figure 27. AMPK expression, Autophagy and mTORC1 signaling after 
treatment with Nigericin.  Western blot to detect the indicated proteins in 





























Figure 28. Sphere formation ability after Nigericin treatment and 
Pyruvate addition. Quantitation of sphere formation by TGS-01 cells that 
were treated with nigericin in culture media containing normal (0.5 mM) or 
high concentration (1.5 mM) of sodium pyruvate. N, normal concentration; 
H, high concentration. Data are the mean ratios of sphere number ± SD 































Figure 29. Therapeutic potential of nigericin for treatment of human 
GBM in vivo.  Quantitation of volumes of tumors in mice that had been 
subcutaneously inoculated with TGS-01 cells and treated with DMSO 
(control) or nigericin. Data are the mean volume ± SD for tumors from 
control (n=6) and nigericin-treated (n=8) mice. Statistical analyses were 




































Figure 30. Immunohistochemical analysis of tumor sections after 
Nigericin treatment.  Immunohistochemistry analyses of tumors that were 
isolated from the mice in (Fig.29) and subjected to HE staining. Data are 
representative of 6 tumors examined/group. Scale bars, 50 µm. V and N 


























Figure 31. Immunohistochemical analysis of tumor sections after 
Nigericin treatment.  Immunohistochemistry analyses of tumors that were 
isolated from the mice in (Fig.29) and subjected to immunostaining with 
Ki67 antibody. Data are representative of 6 tumors examined/group. Scale 






























Figure 32. Therapeutic potential of nigericin for treatment of mouse 
GBM in vivo. Quantitation of volumes of tumors in mice subcutaneously 
inoculated with huKO+ glioma cells (Tsc1f/f;Rosa-CreERT2) and treated 
with/without TAM, which was administrated on day 1 after tumor cell 
inoculation. Nigericin (4 mg/kg/day, ip injection, every 2 days) was 
administered on day 6 post-inoculation. Data are the mean volume ± SD for 
tumors from control (n=10) and nigericin-treated (n=6) mice at 16 days after 
























Figure 33. Therapeutic potential of other compounds for treatment of 
human GBM in vitro. Quantitation of sphere formation in TGS-01 human 
patient-derived GBM cells that were treated with the indicated 
























Figure 34. Therapeutic potential of other compounds for treatment of 
human GBM in vitro. Quantitation of sphere formation in TGS-04 human 
patient-derived GBM cells that were treated with the indicated 








Figure 35. Therapeutic potential of auranofin for treatment of human 
GBM in vivo.  Quantitation of volumes of tumors in the mice that had been 
subcutaneously inoculated with TGS-01 cells and treated with/without 
auranofin. Data are the mean volume ± SD for tumors from control (n=10) 
and auranofin-treated (n=8) mice. Statistical analyses were performed to 















Figure 36. Immunohistochemical analysis of tumor sections after 
Nigericin treatment.  Immunohistochemistry analyses of tumors that were 
isolated from the mice in (Fig.35) and subjected to HE staining. V and N 
indicate vasculature and necrotic area, respectively. Data are representative 





















Figure 37. Immunohistochemical analysis of tumor sections after 
Nigericin treatment.  Immunohistochemistry analyses of tumors that were 
isolated from the mice in (Fig.35) and subjected to immunostaining with 
Ki67 antibody. Data are representative of 8 tumors examined/group. Scale 

















There is much debate over the metabolic status of cancer stem cells in several 
types of tumors, including gliomas. One study reported that GICs are 
primarily glycolytic, and that pharmaceutical inhibition of glycolysis 
decreases the tumorigenicity of these cells(41). However, another study 
found that undifferentiated glioma cells show predominantly mitochondrial 
activity(42). These discrepancies may be due to fact that metabolic status is 
dynamic and easily influenced by factors critical for the determination of 
cancer cell fate, e.g. the cell-of-origin of the tumor, the types of gene 
mutations it bears, and the nutrient conditions in the surrounding 
microenvironment. This complexity makes it difficult to precisely define the 
role of metabolic regulation in a given cancer. This study focused on the 
relationship between metabolic status and mTOR signaling in glioma 
because mTORC1 hyperactivation correlates well with GBM patient 
prognosis (25-27) and found that mTORC1 hyperactivation increase energy 
dependence by mitochondrial OXPHOS. Although hyperactivation of 




metabolism of lipids, nucleotides, and other cellular components, the data 
clearly indicate that enhanced bioenergetic capacity is crucial for expansion 
of GICs, supporting glioma malignancy.  
 Previously, Gupta et.al. developed a drug screening system to select 
specific inhibitors of breast cancer stem cells(43). In that study, mammalian 
epithelial cells were induced to transdifferentiate into a mesenchymal cell 
type by knock-down of E-cadherin. These cells acquired cancer stem cell 
properties, including a CD44+/CD24- surface marker pattern, enhanced 
sphere formation capacity, and therapeutic resistance. Chemical screening 
for compounds that selectively killed mammalian epithelial cells exhibiting 
E-cadherin knock-down revealed that salinomycin (a K+ ionophore) 
suppressed mammary tumor growth and induced epithelial differentiation. 
Nigericin was also selected in that screening, although the effects of this 
agent were not fully characterized. Nigericin is a K+ ionophore that causes 
hyperpolarization of mitochondria, respiratory chain abnormalities and 
reduced ATP production(40,44). In addition, in a nasopharyngeal carcinoma 
cell line, nigericin treatment down-regulated expression of Bim1, a critical 




nigericin appears to have selective effects on cancer stem cells. The 
identification of nigericin as an agent blocking the growth of mTORC1-
driven mouse glioma cells demonstrates that the drug screening system used 
in this study is useful for isolating small molecule compounds capable of 
targeting cancer stem cells.     
It is speculated that a therapeutic approach based on the specific 
targeting of mitochondrial ATP production would trigger a dramatic energy 
imbalance in mTOR-driven glioma cells. Since enhanced protein synthesis 
stimulated by mTORC1 activation induces an increase in ATP consumption 
due to heightened mRNA translation, disruption of this altered balance 
between ATP production and consumption by small molecule compounds 
such as oligomycin might lead to an energy crisis in mTORC1-driven glioma 
cells. It remains possible that nigericin and the other drug candidates selected 
by the screening process have effects in addition to their reduction of ATP 
levels that result in suppression of mTORC1-driven malignant phenotypes. 
For example, nigericin reportedly affects inflammasome activation (46), and 
such additional effects could conceivably contribute to suppression of tumor 




individual agents, the fact that screening system in this study efficiently 
selected several compounds that induce mitochondrial abnormalities 
supports the hypothesis that targeting the altered energy balance in glioma 
cells has the potential to bring therapeutic benefits to glioma patients.  
 The biguanide metformin was originally used for treatment of 
diabetes mellitus but was recently found to have a potent tumor-suppressive 
effect that is independent of its anti-hyperglycemic function(11). A key 
outcome of metformin treatment is inhibition of mitochondrial complex I in 
the electron transport chain, which leads to an increase in the AMP/ATP ratio. 
This imbalance in turn induces activation of AMPK, a critical energy sensor 
that integrates multiple signaling pathways. In this study, results showed that, 
like metformin, nigericin induces AMPK activation associated with 
mTORC1 inhibition. Also the interesting possibility that disruption of a 
cell’s energy balance may induce glioma cell differentiation mediated by 
AMPK activation was uncovered. On the other hand, more detailed 
evaluations of these observations are required for their translational 
application because nigericin administration did not greatly extend the 




shown), presumably due to the inability to penetrate the blood-brain barrier. 
Therefore, the characterization of individual compounds for their 
pharmacokinetics/pharmacodynamics in brain tissues is also important for 
any drug repositioning or drug repurposing designed to treat GBM patients. 
Further investigation is required to determine how these compounds exert 
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In the present study, I investigated the molecular mechanism by which 
mTORC1 hyperactivation causes the malignant phenotypes of glioma cells. 
Results showed that mTORC1 hyperactivation promotes mitochondrial 
energy production, which in turn supports GIC expansion. Importantly, 
using this unique mTORC1-driven glioma model and drug screening system 
to identify small molecule compounds that may be effective for GBM 
therapy. 
In this study, several compounds able to inhibit the mitochondrial activity 
were identified, these compounds reduced ATP levels remarkably and 
inhibited glioma sphere formation. In human patient-derived glioma cells 
TGS-01, Nigericin, which reportedly in previous studies to reduce cancer 
stem cell properties, induced AMPK phosphorylation, associated with 
mTORC1 inactivation, leading to a clear decrease of glioma sphere 
formation. Furthermore, histological and immunohistochemical analysis 
showed that malignant characteristics of human glioma cells were 




mTORC1-driven processes, especially those involved in maintaining a 
cancer cell’s energy balance, may be an effective strategy for glioma patients 
treatment. 
Further investigation is required to determine how these compounds exert 
tumor suppression, and to develop efficient anticancer therapeutics targeting 
the altered energy balance in tumor cells.  
 
 
